Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors.

Journal Article

Pre-existing immunity to human adenovirus serotype 5 (AdHu5) has been shown to suppress the immunogenicity of recombinant Ad5 (rAdHu5) vector-based vaccines for human immunodeficiency virus type 1 (HIV-1) in both preclinical studies and clinical trials. As a potential solution to this problem we developed adenovirus vaccine vectors of chimpanzee origin. In the present study we assessed the immunogenicity of various chimpanzee adenovirus vectors in a prime/boost regimen to HIV-1 envelope and SIV Gag-Pol in rhesus monkeys and their ability to protect against pathogenic viral challenge. Although rAdHu5-primed monkeys had higher magnitude T cell responses than rAdC7 or rAdC68 prior to challenge, the rAdC7-rAdC1/C5 and rAdHu5-rAdC1/C5 immunizations resulted in comparable magnitude recall cellular immune responses and comparable level of control of viremia post-challenge.

Full Text

Duke Authors

Cited Authors

  • Santra, S; Sun, Y; Korioth-Schmitz, B; Fitzgerald, J; Charbonneau, C; Santos, G; Seaman, MS; Ratcliffe, SJ; Montefiori, DC; Nabel, GJ; Ertl, HCJ; Letvin, NL

Published Date

  • September 25, 2009

Published In

Volume / Issue

  • 27 / 42

Start / End Page

  • 5837 - 5845

PubMed ID

  • 19660588

Electronic International Standard Serial Number (EISSN)

  • 1873-2518

Digital Object Identifier (DOI)

  • 10.1016/j.vaccine.2009.07.050

Language

  • eng

Conference Location

  • Netherlands